On a 2025 standalone basis, revenue was KRW 1,929 million, operating loss KRW 1,486 million and net loss KRW 1,909 million. According to FnGuide, operating losses narrowed from KRW 5.3 billion in 2022 to KRW 4.6 billion in 2023 and KRW 3.0 billion in 2024, when revenue was KRW 0.7 billion.
At the end of 2025, total assets were KRW 5,297 million, but total liabilities of KRW 17,201 million and total equity of negative KRW 11,904 million were reported, indicating full capital impairment. We could not confirm the composition of the sharp rise in liabilities, so we withhold interpretation.
The share price was KRW 13,960 at 16:10 KST on March 31, 2026. At 17:02 KST on October 27, 2026 the price was KRW 19,500, down 2.50% from the prior close, and market capitalization was KRW 45.0 billion. Turnover at that time was only KRW 97,500, so price moves on thin order books can be large.
On the clinical side, EPI-001 completed first-patient dosing in its Phase 1/2a trial on April 21, 2026, and on June 23, 2026 the trial moved to cohort 2 after the low-dose safety assessment in cohort 1, with a stated aim of starting Phase 2a enrollment within 2026.
The board resolved on October 14, 2026 to convene an extraordinary general meeting on November 25, 2026 to consider electing a non-executive director and an independent director.